{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T04:56:32Z","timestamp":1773550592250,"version":"3.50.1"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2007,2]]},"DOI":"10.1038\/ncponc0736","type":"journal-article","created":{"date-parts":[[2007,1,26]],"date-time":"2007-01-26T18:53:13Z","timestamp":1169837593000},"page":"101-117","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":366,"title":["Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress"],"prefix":"10.1038","volume":"4","author":[{"given":"Ta-Chiang","family":"Liu","sequence":"first","affiliation":[]},{"given":"Evanthia","family":"Galanis","sequence":"additional","affiliation":[]},{"given":"David","family":"Kirn","sequence":"additional","affiliation":[]}],"member":"297","reference":[{"key":"BFncponc0736_CR1","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1097\/00000441-190412740-00001","volume":"127","author":"G Dock","year":"1904","unstructured":"Dock G (1904) Influence of complicating diseases upon leukemia. AM J Med Sci 127: 563\u2013592","journal-title":"AM J Med Sci"},{"key":"BFncponc0736_CR2","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/1097-0142(195305)6:3<591::AID-CNCR2820060317>3.0.CO;2-M","volume":"6","author":"HR Bierman","year":"1953","unstructured":"Bierman HR  et al. (1953) Remissions in leukemia of childhood following acute infectious disease: staphylococcus and streptococcus, varicella, and feline panleukopenia. Cancer 6: 591\u2013605","journal-title":"Cancer"},{"key":"BFncponc0736_CR3","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/S0140-6736(71)90869-5","volume":"1","author":"G Pasquinucci","year":"1971","unstructured":"Pasquinucci G (1971) Possible effect of measles on leukaemia. Lancet 1: 136","journal-title":"Lancet"},{"key":"BFncponc0736_CR4","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0140-6736(71)92086-1","volume":"2","author":"AZ Bluming","year":"1971","unstructured":"Bluming AZ and Ziegler JL (1971) Regression of Burkitt's lymphoma in association with measles infection. Lancet 2: 105\u2013106","journal-title":"Lancet"},{"key":"BFncponc0736_CR5","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/S0140-6736(81)92286-8","volume":"1","author":"AM Taqi","year":"1981","unstructured":"Taqi AM  et al. (1981) Regression of Hodgkin's disease after measles. Lancet 1: 1112","journal-title":"Lancet"},{"key":"BFncponc0736_CR6","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S0140-6736(71)92788-7","volume":"2","author":"LK Csatary","year":"1971","unstructured":"Csatary LK (1971) Viruses in the treatment of cancer. Lancet 2: 825","journal-title":"Lancet"},{"key":"BFncponc0736_CR7","first-page":"82","volume":"9","author":"NG DePace","year":"1912","unstructured":"DePace NG (1912) Sulla Scomparsa di un enorme cancro begetante del callo dell'utero senza cura chirurgica [Italian]. Ginecolgia 9: 82","journal-title":"Ginecolgia"},{"key":"BFncponc0736_CR8","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1001\/archinte.1978.03630320073024","volume":"138","author":"RM Hansen","year":"1978","unstructured":"Hansen RM and Libnoch JA (1978) Remission of chronic lymphocytic leukemia after smallpox vaccination. Arch Intern Med 138: 1137\u20131138","journal-title":"Arch Intern Med"},{"key":"BFncponc0736_CR9","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/0002-9343(83)90865-3","volume":"75","author":"LB Greentree","year":"1983","unstructured":"Greentree LB (1983) Hodgkin's disease: therapeutic role of measles vaccine. Am J Med 75: 928","journal-title":"Am J Med"},{"key":"BFncponc0736_CR10","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0140-6736(84)90112-0","volume":"1","author":"A Schattner","year":"1984","unstructured":"Schattner A (1984) Therapeutic role of measles vaccine in Hodgkin's disease. Lancet 1: 171","journal-title":"Lancet"},{"key":"BFncponc0736_CR11","doi-asserted-by":"publisher","first-page":"724","DOI":"10.4269\/ajtmh.1951.s1-31.724","volume":"31","author":"CM Southam","year":"1951","unstructured":"Southam CM and Moore AE (1951) West Nile, Ilheus, and Bunyamwera virus infections in man. Am J Trop Med Hyg 31: 724\u2013741","journal-title":"Am J Trop Med Hyg"},{"key":"BFncponc0736_CR12","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1002\/1097-0142(195611\/12)9:6<1211::AID-CNCR2820090624>3.0.CO;2-7","volume":"9","author":"RJ Huebner","year":"1956","unstructured":"Huebner RJ  et al. (1956) Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer 9: 1211\u20131218","journal-title":"Cancer"},{"key":"BFncponc0736_CR13","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1002\/1097-0142(197412)34:6<1907::AID-CNCR2820340609>3.0.CO;2-4","volume":"34","author":"T Asada","year":"1974","unstructured":"Asada T (1974) Treatment of human cancer with mumps virus. Cancer 34: 1907\u20131928","journal-title":"Cancer"},{"key":"BFncponc0736_CR14","first-page":"487","volume":"12","author":"Y Shimizu","year":"1988","unstructured":"Shimizu Y  et al. (1988) Immunotherapy of advanced gynecologic cancer patients utilizing mumps virus. Cancer Detect Prev 12: 487\u2013495","journal-title":"Cancer Detect Prev"},{"key":"BFncponc0736_CR15","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/j.1445-2197.1966.tb03889.x","volume":"35","author":"GW Milton","year":"1966","unstructured":"Milton GW and Brown MM (1966) The limited role of attenuated smallpox virus in the management of advanced malignant melanoma. Aust N Z J Surg 35: 286\u2013290","journal-title":"Aust N Z J Surg"},{"key":"BFncponc0736_CR16","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1136\/bmj.2.5708.512","volume":"2","author":"I Hunter-Craig","year":"1970","unstructured":"Hunter-Craig I  et al. (1970) Use of vaccinia virus in the treatment of metastatic malignant melanoma. BMJ 2: 512\u2013515","journal-title":"BMJ"},{"key":"BFncponc0736_CR17","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/BF00389974","volume":"113","author":"S Arakawa Jr","year":"1987","unstructured":"Arakawa S Jr  et al. (1987) Clinical trial of attenuated vaccinia virus AS strain in the treatment of advanced adenocarcinoma: report on two cases. J Cancer Res Clin Oncol 113: 95\u201398","journal-title":"J Cancer Res Clin Oncol"},{"key":"BFncponc0736_CR18","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/S0022-5347(05)65755-2","volume":"166","author":"LG Gomella","year":"2001","unstructured":"Gomella LG  et al. (2001) Phase I study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer. J Urol 166: 1291\u20131295","journal-title":"J Urol"},{"key":"BFncponc0736_CR19","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1001\/archderm.1974.01630050014003","volume":"109","author":"HH Roenigk Jr","year":"1974","unstructured":"Roenigk HH Jr  et al. (1974) Immunotherapy of malignant melanoma with vaccinia virus. Arch Dermatol 109: 668\u2013673","journal-title":"Arch Dermatol"},{"key":"BFncponc0736_CR20","first-page":"79","volume":"57","author":"A Kawa","year":"1987","unstructured":"Kawa A and Arakawa S (1987) The effect of attenuated vaccinia virus AS strain on multiple myeloma: a case report. Jpn J Exp Med 57: 79\u201381","journal-title":"Jpn J Exp Med"},{"key":"BFncponc0736_CR21","first-page":"55","volume":"4","author":"MJ Mastrangelo","year":"1995","unstructured":"Mastrangelo MJ  et al. (1995) A pilot study demonstrating the feasability of using intratumoral vaccinia injections as a vector for gene transfer. Vaccine Res 4: 55\u201369","journal-title":"Vaccine Res"},{"key":"BFncponc0736_CR22","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0140-6736(75)90172-5","volume":"2","author":"JD Everall","year":"1975","unstructured":"Everall JD  et al. (1975) Treatment of primary melanoma by intralesional vaccinia before excision. Lancet 2: 583\u2013586","journal-title":"Lancet"},{"key":"BFncponc0736_CR23","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1002\/1097-0142(195209)5:5<1025::AID-CNCR2820050518>3.0.CO;2-Q","volume":"5","author":"CM Southam","year":"1952","unstructured":"Southam CM and Moore AE (1952) Clinical studies of viruses as antineoplastic agents with particular reference to Egypt 101 virus. Cancer 5: 1025\u20131034","journal-title":"Cancer"},{"key":"BFncponc0736_CR24","first-page":"37","volume":"21","author":"Y Okuno","year":"1978","unstructured":"Okuno Y  et al. (1978) Studies on the use of mumps virus for treatment of human cancer. Biken J 21: 37\u201349","journal-title":"Biken J"},{"key":"BFncponc0736_CR25","doi-asserted-by":"publisher","first-page":"711","DOI":"10.3181\/00379727-119-30278","volume":"119","author":"HW Toolan","year":"1965","unstructured":"Toolan HW  et al. (1965) H-1 Virus viremia in the human. Proc Soc Exp Biol Med 119: 711\u2013715","journal-title":"Proc Soc Exp Biol Med"},{"key":"BFncponc0736_CR26","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJM196409242711302","volume":"271","author":"EF Wheelock","year":"1964","unstructured":"Wheelock EF and Dingle JH (1964) Observations on the repeated administration of viruses to a patient with acute leukemia: a preliminary report. N Engl J Med 271: 645\u2013651","journal-title":"N Engl J Med"},{"key":"BFncponc0736_CR27","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/1097-0142(196507)18:7<863::AID-CNCR2820180714>3.0.CO;2-V","volume":"18","author":"WA Cassel","year":"1965","unstructured":"Cassel WA and Garrett RE (1965) Newcastle Disease Virus as an antineoplastic agent. Cancer 18: 863\u2013868","journal-title":"Cancer"},{"key":"BFncponc0736_CR28","first-page":"619","volume":"17","author":"LK Csatary","year":"1993","unstructured":"Csatary LK  et al. (1993) Attenuated veterinary virus vaccine for the treatment of cancer. Cancer Detect Prev 17: 619\u2013627","journal-title":"Cancer Detect Prev"},{"key":"BFncponc0736_CR29","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1001\/jama.281.17.1588-a","volume":"281","author":"LK Csatary","year":"1999","unstructured":"Csatary LK and Bakacs T (1999) Use of Newcastle disease virus vaccine (MTH-68\/H) in a patient with high-grade glioblastoma. JAMA 281: 1588\u20131589","journal-title":"JAMA"},{"key":"BFncponc0736_CR30","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1023\/B:NEON.0000021735.85511.05","volume":"67","author":"LK Csatary","year":"2004","unstructured":"Csatary LK  et al. (2004) MTH-68\/H oncolytic viral treatment in human high-grade gliomas. J Neuro-oncol 67: 83\u201393","journal-title":"J Neuro-oncol"},{"key":"BFncponc0736_CR31","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/89901","volume":"7","author":"D Kirn","year":"2001","unstructured":"Kirn D  et al. (2001) Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med 7: 781\u2013787","journal-title":"Nat Med"},{"key":"BFncponc0736_CR32","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1200\/JCO.2002.08.042","volume":"20","author":"AL Pecora","year":"2002","unstructured":"Pecora AL  et al. (2002) Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol 20: 2251\u20132266","journal-title":"J Clin Oncol"},{"key":"BFncponc0736_CR33","first-page":"618","volume":"5","author":"RM Lorence","year":"2003","unstructured":"Lorence RM  et al. (2003) Overview of phase I studies of intravenous administration of PV701, an oncolytic virus. Curr Opin Mol Ther 5: 618\u2013624","journal-title":"Curr Opin Mol Ther"},{"key":"BFncponc0736_CR34","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ymthe.2005.08.016","volume":"13","author":"AI Freeman","year":"2006","unstructured":"Freeman AI  et al. (2006) Phase I\/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther 13: 221\u2013228","journal-title":"Mol Ther"},{"key":"BFncponc0736_CR35","first-page":"a24","volume":"21","author":"DG Morris","year":"2002","unstructured":"Morris DG  et al. (2002) A phase I clinical trial evaluating intralesional Reolysin (reovirus) in histologically confirmed malignancies [abstract # 92]. Proc Am Soc Clin Oncol 21: a24","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BFncponc0736_CR36","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/sj.gt.3301377","volume":"8","author":"D Kirn","year":"2001","unstructured":"Kirn D (2001) Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Ther 8: 89\u201398","journal-title":"Gene Ther"},{"key":"BFncponc0736_CR37","doi-asserted-by":"publisher","first-page":"4357","DOI":"10.1158\/1078-0432.CCR-03-0443","volume":"10","author":"S Morley","year":"2004","unstructured":"Morley S  et al. (2004) The dl1520 virus is found preferentially in tumor tissue after direct intratumoral injection in oral carcinoma. Clin Cancer Res 10: 4357\u20134362","journal-title":"Clin Cancer Res"},{"key":"BFncponc0736_CR38","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/sj.gt.3301398","volume":"8","author":"S Mulvihill","year":"2001","unstructured":"Mulvihill S  et al. (2001) Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Ther 8: 308\u2013315","journal-title":"Gene Ther"},{"key":"BFncponc0736_CR39","first-page":"6359","volume":"60","author":"J Nemunaitis","year":"2000","unstructured":"Nemunaitis J  et al. (2000) Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res 60: 6359\u20136366","journal-title":"Cancer Res"},{"key":"BFncponc0736_CR40","first-page":"798","volume":"6","author":"I Ganly","year":"2000","unstructured":"Ganly I  et al. (2000) A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 6: 798\u2013806","journal-title":"Clin Cancer Res"},{"key":"BFncponc0736_CR41","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1200\/JCO.2001.19.2.289","volume":"19","author":"J Nemunaitis","year":"2001","unstructured":"Nemunaitis J  et al. (2001) Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 19: 289\u2013298","journal-title":"J Clin Oncol"},{"key":"BFncponc0736_CR42","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.ymthe.2004.07.021","volume":"10","author":"EA Chiocca","year":"2004","unstructured":"Chiocca EA  et al. (2004) A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther 10: 958\u2013966","journal-title":"Mol Ther"},{"key":"BFncponc0736_CR43","first-page":"1562","volume":"20","author":"PA Vasey","year":"2002","unstructured":"Vasey PA  et al. (2002) Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent\/refractory epithelial ovarian cancer. J Clin Oncol 20: 1562\u20131569","journal-title":"J Clin Oncol"},{"key":"BFncponc0736_CR44","first-page":"693","volume":"9","author":"D Makower","year":"2003","unstructured":"Makower D  et al. (2003) Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies. Clin Cancer Res 9: 693\u2013702","journal-title":"Clin Cancer Res"},{"key":"BFncponc0736_CR45","first-page":"6070","volume":"62","author":"T Reid","year":"2002","unstructured":"Reid T  et al. (2002) Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res 62: 6070\u20136079","journal-title":"Cancer Res"},{"key":"BFncponc0736_CR46","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1089\/10430340150218369","volume":"12","author":"NA Habib","year":"2001","unstructured":"Habib NA  et al. (2001) E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors. Hum Gene Ther 12: 219\u2013226","journal-title":"Hum Gene Ther"},{"key":"BFncponc0736_CR47","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/sj.cgt.7700431","volume":"9","author":"N Habib","year":"2002","unstructured":"Habib N  et al. (2002) Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma. Cancer Gene Ther 9: 254\u2013259","journal-title":"Cancer Gene Ther"},{"key":"BFncponc0736_CR48","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1038\/sj.gt.3301424","volume":"8","author":"J Nemunaitis","year":"2001","unstructured":"Nemunaitis J  et al. (2001) Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther 8: 746\u2013759","journal-title":"Gene Ther"},{"key":"BFncponc0736_CR49","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1200\/JCO.2003.09.114","volume":"21","author":"O Hamid","year":"2003","unstructured":"Hamid O  et al. (2003) Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer. J Clin Oncol 21: 1498\u20131504","journal-title":"J Clin Oncol"},{"key":"BFncponc0736_CR50","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1038\/78638","volume":"6","author":"FR Khuri","year":"2000","unstructured":"Khuri FR  et al. (2000) A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 6: 879\u2013885","journal-title":"Nat Med"},{"key":"BFncponc0736_CR51","first-page":"310","volume":"22","author":"ZY Yuan","year":"2003","unstructured":"Yuan ZY  et al. (2003) Safety of an E1B deleted adenovirus administered intratumorally to patients with cancer [Chinese]. Ai Zheng 22: 310\u2013313","journal-title":"Ai Zheng"},{"key":"BFncponc0736_CR52","doi-asserted-by":"publisher","first-page":"3634","DOI":"10.3748\/wjg.v10.i24.3634","volume":"10","author":"W Lu","year":"2004","unstructured":"Lu W  et al. (2004) Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial. World J Gastroenterol 10: 3634\u20133638","journal-title":"World J Gastroenterol"},{"key":"BFncponc0736_CR53","first-page":"1666","volume":"23","author":"ZJ Xia","year":"2004","unstructured":"Xia ZJ  et al. (2004) Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus [Chinese]. Ai Zheng 23: 1666\u20131670","journal-title":"Ai Zheng"},{"key":"BFncponc0736_CR54","first-page":"7464","volume":"61","author":"TL DeWeese","year":"2001","unstructured":"DeWeese TL  et al. (2001) A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 61: 7464\u20137472","journal-title":"Cancer Res"},{"key":"BFncponc0736_CR55","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ymthe.2006.02.011","volume":"14","author":"EJ Small","year":"2006","unstructured":"Small EJ  et al. (2006) A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther 14: 107\u2013117","journal-title":"Mol Ther"},{"key":"BFncponc0736_CR56","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/sj.gt.3301205","volume":"7","author":"JM Markert","year":"2000","unstructured":"Markert JM  et al. (2000) Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 7: 867\u2013874","journal-title":"Gene Ther"},{"key":"BFncponc0736_CR57","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1089\/hum.2006.17.1214","volume":"17","author":"M Kemeny","year":"2006","unstructured":"Kemeny M  et al. (2006) Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Hum Gene Ther 17: 1214\u20131224","journal-title":"Hum Gene Ther"},{"key":"BFncponc0736_CR58","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/sj.cgt.7700066","volume":"6","author":"MJ Mastrangelo","year":"1999","unstructured":"Mastrangelo MJ  et al. (1999) Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther 6: 409\u2013422","journal-title":"Cancer Gene Ther"},{"key":"BFncponc0736_CR59","doi-asserted-by":"publisher","first-page":"6737","DOI":"10.1158\/1078-0432.CCR-06-0759","volume":"12","author":"JC Hu","year":"2006","unstructured":"Hu JC  et al. (2006) A phase I clinical trial with OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 12: 6737\u20136747","journal-title":"Clin Cancer Res"},{"key":"BFncponc0736_CR60","first-page":"4968","volume":"62","author":"SO Freytag","year":"2002","unstructured":"Freytag SO  et al. (2002) Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res 62: 4968\u20134976","journal-title":"Cancer Res"},{"key":"BFncponc0736_CR61","first-page":"7497","volume":"63","author":"SO Freytag","year":"2003","unstructured":"Freytag SO  et al. (2003) Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res 63: 7497\u20137506","journal-title":"Cancer Res"},{"key":"BFncponc0736_CR62","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1158\/1078-0432.CCR-05-2038","volume":"12","author":"SA Laurie","year":"2006","unstructured":"Laurie SA  et al. (2006) A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization. Clin Cancer Res 12: 2555\u20132562","journal-title":"Clin Cancer Res"},{"key":"BFncponc0736_CR63","first-page":"s14s","volume":"22","author":"SJ Hotte","year":"2003","unstructured":"Hotte SJ  et al. (2003) Slow intravenous infusion of PV701, an oncolytic virus: final results of a phase I study [abstract # 3037]. Proc Am Soc Clin Oncol 22: s14s","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BFncponc0736_CR64","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1056\/NEJMsa042220","volume":"352","author":"E Horstmann","year":"2005","unstructured":"Horstmann E  et al. (2005) Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 352: 895\u2013904","journal-title":"N Engl J Med"},{"key":"BFncponc0736_CR65","first-page":"555","volume":"9","author":"JR Hecht","year":"2003","unstructured":"Hecht JR  et al. (2003) A phase I\/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res 9: 555\u2013561","journal-title":"Clin Cancer Res"},{"key":"BFncponc0736_CR66","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/sj.gt.3302436","volume":"12","author":"E Galanis","year":"2005","unstructured":"Galanis E  et al. (2005) Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Ther 12: 437\u2013445","journal-title":"Gene Ther"},{"key":"BFncponc0736_CR67","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1038\/sj.gt.3301512","volume":"8","author":"T Reid","year":"2001","unstructured":"Reid T  et al. (2001) Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Ther 8: 1618\u20131626","journal-title":"Gene Ther"},{"key":"BFncponc0736_CR68","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/sj.cgt.7700585","volume":"10","author":"J Nemunaitis","year":"2003","unstructured":"Nemunaitis J  et al. (2003) Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients. Cancer Gene Ther 10: 341\u2013352","journal-title":"Cancer Gene Ther"},{"key":"BFncponc0736_CR69","first-page":"1317","volume":"63","author":"LM Wein","year":"2003","unstructured":"Wein LM  et al. (2003) Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery. Cancer Res 63: 1317\u20131324","journal-title":"Cancer Res"},{"key":"BFncponc0736_CR70","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/sj.gt.3301184","volume":"7","author":"R Rampling","year":"2000","unstructured":"Rampling R  et al. (2000) Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 7: 859\u2013866","journal-title":"Gene Ther"},{"key":"BFncponc0736_CR71","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/sj.gt.3301664","volume":"9","author":"V Papanastassiou","year":"2002","unstructured":"Papanastassiou V  et al. (2002) The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther 9: 398\u2013406","journal-title":"Gene Ther"},{"key":"BFncponc0736_CR72","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1038\/sj.gt.3302289","volume":"11","author":"S Harrow","year":"2004","unstructured":"Harrow S  et al. (2004) HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Ther 11: 1648\u20131658","journal-title":"Gene Ther"},{"key":"BFncponc0736_CR73","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S0140-6736(00)04048-4","volume":"357","author":"RM MacKie","year":"2001","unstructured":"MacKie RM  et al. (2001) Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet 357: 525\u2013526","journal-title":"Lancet"},{"key":"BFncponc0736_CR74","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0140-6736(71)92232-X","volume":"1","author":"Gross","year":"1971","unstructured":"Gross (1971) Measles and leukaemia. Lancet 1: 397\u2013398","journal-title":"Lancet"}],"container-title":["Nature Clinical Practice Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/ncponc0736.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ncponc0736","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/ncponc0736","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/ncponc0736.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T17:19:49Z","timestamp":1684862389000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncponc0736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2]]},"references-count":74,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["BFncponc0736"],"URL":"https:\/\/doi.org\/10.1038\/ncponc0736","relation":{},"ISSN":["1743-4254","1743-4262"],"issn-type":[{"value":"1743-4254","type":"print"},{"value":"1743-4262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,2]]},"assertion":[{"value":"5 February 2006","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2006","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D Kirn has declared he is has ownership in and employment by Jennerex Biotherapeutics ULC, a company developing development oncolytic viruses for cancer patients. The other authors declared they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}